Clinical trials: Hemostatic Disorders
Von Willebrand Diseases
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other…
- Trial name
- NCT05776069
- Testing
- VGA039
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Vega Therapeutics, Inc
Hemophilia A
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
The main purposes of this study are to determine if use of emicizumab prophylaxis treatment reduces number of bleeding episodes, if it improves quality of life of individuals and if improves arthropathy in persons with hemophilia…
- Trial name
- ML43518 (NCT06104826)
- Testing
- Emicizumab
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Newark Beth Israel Medical Center
Coagulation, Therapeutic Uses
Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose Design 9 System
The QuickClose Design 9 is a prospective, non randomized study, to evaluate the safety and efficacy of the QuickClose design 9 closure device.
- Conditions
- Coagulation, Therapeutic Uses, Pharmacologic Actions
- Trial name
- NCT01121510
- Testing
- closure device
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CardioDex
Ehlers-Danlos Syndrome, Classic
IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients
The investigators want to inject insulin-like growth factor-I (IGF-I) into the patella tendon of Ehlers-Danlos patients and healthy controls to evaluate the response in collagen synthesis.
- Trial name
- NCT01446783
- Testing
- mecasermin, Saline
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Hemostatic Disorder
Hemostatic Disorders on Intensive Care Patients.
1. To assess the incidence of hemostatic disorders among ICU patients. 2. To establish a relationship between supportive treatment and survival in patients with coagulopathy in ICU. 3.
- Trial name
- NCT04179357
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hereditary Hemorrhagic Telangiectasia
Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT) results from genetic deregulation of angiogenesis. It is characterized by mucocutaneous telangiectasia responsible for recurrent epistaxis affecting quality of life (anaemia, iron…
- Trial name
- TangRO (NCT03572556)
- Testing
- Blood samples, Epistaxis charts
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Advanced Malignant Solid Neoplasm, Caregiver
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
This trial studies the frequency of cachexia in ambulatory cancer patients and the psychological burden in patients and their primary caregivers who are referred to an outpatient supportive care clinic.
- Conditions
- Advanced Malignant Solid Neoplasm, Caregiver, Metastatic Malignant Solid Neoplasm, Recurrent Leukemia
- Trial name
- NCT04090619
- Testing
- Questionnaire Administration
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Collagen Degeneration, Wrinkle
The Effects of Almond on Facial Skin Collagen and Wrinkles
Investigate the effects of almond consumption on collagen production, elastin levels, wrinkles, and pigmentation among premenopausal women and postmenopausal women belonging to all Fitzpatrick skin types.
- Conditions
- Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin
- Trial name
- NCT06074276
- Testing
- Food: whole almonds, Food: non-nut snack
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Myeloma
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
- Trial name
- NCT01174082
- Testing
- KLH Vaccine, KLH-id Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma
This prospective study aims to investigate serum soluble B-cell maturation antigen (sBCMA) as a non-invasive marker in patients with multiple myeloma and to compare its levels with healthy controls.
- Trial name
- NCT07855718
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Adenotonsillar Hypertrophy, Tonsillitis
Comparison of Floseal Hemostasis Tonsillectomy With Coblation Tonsillectomy and Cautery Hemostasis Tonsillectomy
The purpose of this study is to evaluate a new method of hemostasis, floseal gel, in tonsillectomy and adenoidectomy, with the goal of decreasing post operative and intraoperative morbidity.
- Conditions
- Adenotonsillar Hypertrophy, Tonsillitis, Obstructive Sleep Apnea
- Trial name
- NCT00459927
- Testing
- Floseal tonsillectomy, Coblation tonsillectomy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Multiple Myeloma
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.
Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM.
- Trial name
- MYELODOM (NCT04260490)
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
High-risk Smoldering Multiple Myeloma, Multiple Myeloma
DARA RVD For High Risk SMM
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and…
- Trial name
- PRISM (NCT04775550)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Omar Nadeem, MD
Multiple Myeloma and Malignant Plasma Cell Neoplasms
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification.
- Trial name
- NCT06717113
- Testing
- 18F-FDG, 68Ga-BC1
- Where
- 2 sites in China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Glanzmann Thrombasthenia
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study
Glanzmann thrombasthenia is a rare genetic disorder caused by the absence or the dysfunction of the main receptor present on the surface of platelets, integrin αIIbβ3 or GPIIb-IIIa.
- Trial name
- GLAT (NCT06234813)
- Testing
- Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen, : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM, Thrombin Generation Assay (TGA) in PRP using TF trigger
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Pseudoxanthoma Elasticum, Tomography, Optical Coherence
CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum
This observational study sets out to compare choriocapillaris flow deficits between healthy control subjects and patients with pseudoxanthoma elasticum.
- Conditions
- Pseudoxanthoma Elasticum, Tomography, Optical Coherence, Retinal Disease
- Trial name
- CHOPXE (NCT07006649)
- Testing
- Opthtalmologic diagnosis tests
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Multiple Myeloma
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy.
- Trial name
- NCT07225738
- Testing
- Non-Interventional Study
- Where
- 11 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
COVID-19, Endothelial Dysfunction
The Glycocalyx in COVID-19 Patients. A Pilot Study
The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS.
- Conditions
- COVID-19, Endothelial Dysfunction, Coagulation Disorder
- Trial name
- Glycovid-19 (NCT05137249)
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Bleeding Disorder
Bleeding of Unknown Cause: a Swiss Case-control Study
The goal of this prospective cohort is to identified specific biological patterns in patients with a bleeding of unknown cause and to study the specific mechanisms of the bleeding disorder for each subset of patients.
- Trial name
- SWISS-BUC (NCT05713734)
- Testing
- Thrombin generation, Fibrinolysis, Fibrin clot structure
- Where
- 7 sites in Switzerland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva